Seattle Genetics, co-founded by Dr. Clay Siegall is the leader in cancer treatments and therapies. At the core, it’s foundation is the passion for helping patients by providing innovative research and drug development.
Dr. Siegall, a scientist by training places great emphasis on targeted cancer treatments. With his leadership, Dr. Siegall and Seattle Genetics have joined several pharamceutical companies in the development of Antibody Drug Conjugates (ADC’s). The development of these ADC’s have generated $300 million to date. Seattle Genetics has more than 20 ADC’s in clinical trails at this time. The development of these ADC’s is made possible by using Seattle Genetics’ technology.
Seattle Genetics researches and develops antibody-based cancer therapies. In 2011, the Food and Drug Administration (FDA), granted approval for the drug Adecetrics (brentuvimab vendotin). With it’s research and development, Seattle Genetics is the leading company for antibody technologies.
Dr. Siegall began his career in 1988 at the National Cancer Institute. Since then, Dr. Siegall has become the co-founder of Seattle Genetics, published more than 70 publications and holds 15 patents. In addition to his cancer research and development, Dr. Siegall serves on the Board of Directors for Alder Biopharmaceuticals, Mirna Therapeutics, and in 2014 became a board memeber for Ultragenyx.
With his years of experience, Dr. Clay Sieagll is helping Seattle Gentetics become the frontline for cancer treatments and therapies. It’s through their dedication to treating cancer and helping patients that this company has taken the leadership position in this field.
This research and development is truly making it’s mark on cancer treatments. Afterall, Seattle Genetics’ core foundation is helping patients.